BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10213180)

  • 21. Is Hyperhomocyst(e)inemia a humoral predictor of coronary heart disease?
    Virdis A; Ghiadoni L; Versari D; Salvetti G; Pinto S; Favilla S; Taddei S; Salvetti A
    Curr Pharm Des; 2005; 11(17):2187-97. PubMed ID: 16026288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Causes and consequences of hyperhomocyst(e)inemia.
    Pietrzik K; Brönstrup A
    Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperhomocyst(e)inemia induces multiorgan damage.
    Miller A; Mujumdar V; Shek E; Guillot J; Angelo M; Palmer L; Tyagi SC
    Heart Vessels; 2000; 15(3):135-43. PubMed ID: 11289502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
    Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
    Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperhomocyst(e)inemia: a risk factor for cerebrovascular disease.
    Parnetti L; Caso V; Amici S; Lanari A; Gallai V; Bottiglieri T
    Clin Exp Hypertens; 2002; 24(7-8):501-9. PubMed ID: 12450225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
    Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
    Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men.
    von Eckardstein A; Malinow MR; Upson B; Heinrich J; Schulte H; Schönfeld R; Köhler E; Assmann G
    Arterioscler Thromb; 1994 Mar; 14(3):460-4. PubMed ID: 8123652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
    Falcon CR; Cattaneo M; Panzeri D; Martinelli I; Mannucci PM
    Arterioscler Thromb; 1994 Jul; 14(7):1080-3. PubMed ID: 8018663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis.
    Lee YK; Kwon YJ; Yoon JW; Oh KS; Cha DR; Cho WY; Huh K; Pyo HJ; Kim HK
    J Korean Med Sci; 1999 Apr; 14(2):193-8. PubMed ID: 10331567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.
    Kang SS; Wong PW
    Atherosclerosis; 1996 Jan; 119(2):135-8. PubMed ID: 8808490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
    Stühlinger MC; Stanger O
    Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.
    Joven J; Arcelús R; Camps J; Ordóñez-Llanos J; Vilella E; González-Sastre F; Blanco-Vaca F
    J Mol Med (Berl); 2000; 78(3):147-54. PubMed ID: 10868477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperhomocyst(e)inemia--determining factors and treatment.
    Genest J
    Can J Cardiol; 1999 Apr; 15 Suppl B():35B-38B. PubMed ID: 10350684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.
    Tawakol A; Omland T; Gerhard M; Wu JT; Creager MA
    Circulation; 1997 Mar; 95(5):1119-21. PubMed ID: 9054838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homocysteine as a novel risk factor for atherosclerosis.
    Guthikonda S; Haynes WG
    Curr Opin Cardiol; 1999 Jul; 14(4):283-91. PubMed ID: 10448607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease.
    Stanger O; Weger M; Renner W; Konetschny R
    Clin Chem Lab Med; 2001 Aug; 39(8):725-33. PubMed ID: 11592442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
    Lentz SR; Malinow MR; Piegors DJ; Bhopatkar-Teredesai M; Faraci FM; Heistad DD
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2930-4. PubMed ID: 9409278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperhomocyst(e)inemia--an independent risk factor of stroke].
    Lalouschek W; Aull S; Deecke L; Schnider P; Uhl F; Zeiler K
    Fortschr Neurol Psychiatr; 1996 Jul; 64(7):271-7. PubMed ID: 8765893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.
    Woo KS; Chook P; Lolin YI; Cheung AS; Chan LT; Sun YY; Sanderson JE; Metreweli C; Celermajer DS
    Circulation; 1997 Oct; 96(8):2542-4. PubMed ID: 9355891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.
    Stühlinger MC; Oka RK; Graf EE; Schmölzer I; Upson BM; Kapoor O; Szuba A; Malinow MR; Wascher TC; Pachinger O; Cooke JP
    Circulation; 2003 Aug; 108(8):933-8. PubMed ID: 12912818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.